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ABSTRACT
A role for nephrologists in the management of a poisoned
patient involves evaluating the indications for, and meth-
ods of, enhancing the elimination of a poison. Nephrolo-
gists are familiar with the various extracorporeal
treatments (ECTRs) used in the management of impaired
kidney function, and their respective advantages and dis-
advantages. However, these same skills and knowledge
may not always be considered, or applicable, when pre-
scribing ECTR for the treatment of a poisoned patient.
Maximizing solute elimination is a key aim of such treat-
ments, perhaps more so than in the treatment of uremia,
because ECTR has the potential to reverse clinical toxicity
and shorten the duration of poisoning. This manuscript
reviews the various principles that govern poison elimina-
tion by ECTR (diffusion, convection, adsorption, and
centrifugation) and how components of the ECTR can be
adjusted to maximize clearance. Data supporting these
recommendations will be presented, whenever available.
Principles of Poison Removal
The various methods available for poison removal
by ECTR are diffusion, convection, adsorption, and
centrifugation. This manuscript reviews the princi-
ples and parameters that may influence poison clear-
ance. A detailed understanding of these principles is
useful for the nephrologist because they guide how
adjustments to the ECTR prescription can optimize
solute clearance. These principles can be used to
individualize ECTR in the context of its indication.
Diffusion
Thomas Graham first suggested the concept of
dialysis in 1861, based on the process of diffusion.
During diffusion, the movement of particles (sol-
utes) is driven by a concentration gradient from one
compartment to another through a semi-permeable
membrane. In the case of hemodialysis, the two
compartments are the blood and dialysate and
mainly small molecules (defined as a molecular
weight (MW) less than 500–1000 Da), and some
middle molecules, readily cross the filter membrane.
Operational characteristics influencing diffusive
clearance include the magnitude of the concentra-
tion gradient (blood and dialysate flow rates), dura-
tion of therapy, and the filter composition. These
factors will be discussed here and are also summa-
rized in Table 1.
Maximization of Blood and Countercurrent
Dialysate Flow Rates
Principles. Both blood (QB) and dialysate (QD)
flows influence solute clearance. In general, the
maximum possible clearance corresponds to the
slower of the two flows, which will be the rate-limit-
ing step. In intermittent hemodialysis (IHD), QB is
usually slower than QD, whereas the opposite is true
in continuous venovenous hemodialysis (CVVHD).
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BLOOD PURIFICATION IN POISONING
Therefore, when adjusting the dialysis prescription
to maximize solute clearance, the greatest impact
will follow an increase in QB in IHD, compared
with an increase in QD in CVVHD.
Because the mobility of the solute between the
compartments influences clearance, the clearance of
small water-soluble solutes will exceed that of larger
particles.
Peritoneal dialysis (PD) has been used for the
treatment of acute poisoning and clearance is also
influenced by QD. However, PD is not usually rec-
ommended in the treatment of poisoning because
clearance is universally less than that achieved with
other ECTRs.
Supporting Data. In IHD, an increase of 100–
200 ml/minute in QB will significantly enhance the
clearance of small solutes like urea (1–8). A similar
effect is, therefore, expected for small poisons like
lithium and alcohols.
In IHD, some authors suggest targeting a QD/QB
ratio >2.5:1 to ensure that clearance of small molecules
is not restricted by dialysate flow (9). Therefore, if a
QB of 400 ml/minute is achievable, QD should opti-
mally be 1000 ml/minute, although any increment over
600 ml/minute only modestly improves performance
(10). A mechanism by which QD increases clearance is
via better distribution of flow between the filter bun-
dles, thereby increasing the effective surface of the
filter. In addition, countercurrent direction of dialysate
flow provides 20–30% better clearances for small
molecules than a concurrent direction of flow (11).
In CVVHD, an increase in QD will improve small
solute clearance with a near-linear relationship
(Fig. 1) (12–17).
Although there are some limitations, these princi-
ples also apply to protein-bound toxins and medi-
cines such as phenol, p-cresol, hippurate,
carbamazepine, and valproic acid (15,18–20), partic-
ularly when protein binding is saturated (21).
There are data supporting the application of these
principles in the treatment of poisoned patients. For
example, increasing QB from 200 to 300 ml/minute
in IHD increases the clearance of valproic acid from
43 to 80 ml/minute (22). Increasing QB also
increases the clearance of middle molecules like
vancomycin when a high-flux filter is used (23). Sim-
ilar results were shown in poisonings to phenobarbi-
TABLE 1. Summary of the most important parameters for optimizing clearance with the different extracorporeal therapies
Operational parameters to optimize clearance
For small molecules
(MW <500–1000 Da) For middle-sized molecules
For protein-bound
molecules (>80%)
Diffusion (e.g. IHD) High QB (up to 400 ml/minute)
a
Ratio QD: QB ≥ 2.5
High-efficiency filter
Adding a second filter?
Convection preferred over diffusiona
High-flux filtera with a large
surface areaa
High QB
Adding a second filter?
High QD
Filter with a large
surface area
Adding a second filter?
Convection
(Intermittent hemofiltration)
High QB
a
High QUF
a
Maximize postdilution then
add predilution
High QB
High QUF
a, maximize postdilution
then add predilution
High-flux filtera
High-flux filter
Predilution?
Convection &/or diffusion
(in CRRT)
High Qeffluent (QD > QUF)
a
High QB
Maximize postdilution then
add predilution
High-efficiency filter
Filter changed <48 hours
Adding a second filter?
High Qeffluent (QUF > QD)
a
Maximize convection: CVVH >
CVVHDF (because replacement
fluid is greater)
High QB
High-flux filtera
Filter changed <48 hours
Adding a second filter?
Adsorption (e.g. IHP) Charcoal vs. resin column (depending on poison)*
High QB (max 350 mL/min)
Filter change <4 hours
Centrifugation
(e.g. therapeutic plasma
exchange)
Centrifugation or filtration
≥2 plasma volumes exchanged*
Central catheter
High QB (100–200 ml/min for filtration and 100 ml/min for centrifugation)
Replacement fluid tailored to the poison
Heparin vs. citrate anticoagulation
For all processes Right jugular catheter ≥ femoral. For a femoral site, use catheter >20 cm long. Subclavian site
probably equivalent to jugular but avoid in patients at risk for end-stage renal disease.
Both subclavian and jugular sites may require X-ray confirmation of placement.
Longer treatment time
CRRT, continuous renal replacement therapy; CVVH, continuous venovenous hemofiltration; CVVHDF, continuous venovenous he-
modiafiltration; MARS, molecular adsorbent recirculating system; SPAD, single pass albumin dialysis; QB, blood flow rate; QD, dialy-
sate flow rate; QUF, ultrafiltration rate.
aMost important.
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tal, lithium, and phenytoin, where clearance platea-
ued when QB exceeded approximately 300 ml/min-
ute in the context of QD 500 ml/minute (24,25).
Peritoneal dialysis (PD) also uses the principle of
passive diffusion, although fluid and solute
exchange occurs in the peritoneal cavity across the
peritoneal membrane. The use of PD in poisoning
has almost disappeared due to its limited clearance
capacity compared with IHD (26–29). In PD,
increasing the dialysate flow rate (QD) maximizes
clearance. Increasing QD is possible by increasing
the frequency and volume of the exchanges (28,30–
32). Extremely high dialysate flows, provided by
continuous-flow PD over a short period of time,
may allow good clearance of solutes that readily dif-
fuse through the peritoneal membrane. For exam-
ple, a urea clearance of 35 ml/minute was achieved
when dialysate flow was 6–9 l/hour (33,34), and
48 ml/minute when using a double-lumen catheter
(35). In another study, methanol clearance was
70 ml/minute with a dialysate flow of 6 l/hour (36),
a significant result but still minor compared with
that obtained by IHD (37). Small MW clearance
may be enhanced when PD is performed in the
supine position (38). Tidal PD does not appear to
improve clearance over intermittent PD (39).
Limitations. Increases in QB and QD are associ-
ated with a lesser increase in clearance of middle-
sized molecules by diffusion, such as vitamin B12
(40) (MW 1355 Da) and b2-microglobulin (1,9,10)
(MW 11,000 Da) (Fig. 1), and no significant change
for larger molecules like dextran (41).
QB is usually limited to <400 ml/minute when
using an intravascular catheter due to blood turbu-
lence and resistance in the tubing. However,
advances in catheter design may allow for greater
QB (42–44). Notably, however, increasing levels of
blood recirculation (compromising clearance) occur
when QB exceeds 400 ml/minute in femoral vein
catheters.
In IHD, increasing the QD:QB ratio does not pro-
portionally increase solute clearance. For example,
for a QB of 300 ml/minute, augmenting QD from
300 to 500 ml/minute will increase clearance by a
greater proportion than an increase from 500 to
800 ml/minute, regardless of the filter used
(1,2,4,9,45). Augmenting QD increases clearance by
approximately 10–20% for small MW molecules (1–
3,10,13,20,46), but does not affect the clearance of
larger molecules (13,14,47). A dialysate flow over
800 ml/minute may exceed the operational capacity
of some machines and/or increase the cost of the
treatment due to the larger volume of dialysate
solutions.
In CVVHD, because QB is already approximately
three times higher than QD, there is no benefit from
further increases in QB, at least with a QD up to
4 l/hour (12,15).
Use of a High-Efficiency Filter, Particularly for
Smaller Solutes
Principles. Efficiency and flux are two character-
istics of filters that relate to solute clearance, reflect-
ing filter surface area and composition.
Efficiency refers to the capacity to clear urea,
which is a surrogate measure of low MW solutes,
and is quantified by the product of its mass transfer
area coefficient (Ko) and surface area (A), KoA. The
higher the KoA of a filter, the higher will be the
clearance of small solutes. The actual clearance
achieved by a particular filter depends on the MW
of the solute and other specifics of the dialysis pre-
scription, in particular the QB and QD, as well as
ultrafiltration. Therefore, some aspects relating to
convection are also discussed here.
In contrast, flux refers to the permeability of the
filter to middle-sized MW solutes; it is most often
assessed using b2-microglobulin (MW 11,000
daltons). The ultrafiltration capacity of the filter,
quantified according to the ultrafiltration coefficient
(KUF), typically correlates with this (48).
The simultaneous use of two filters or machines
will further increase clearance.
Supporting Data. Extracorporeal membranes can
be characterized by their surface area, material,
morphology, fiber length and thickness, permeabil-
ity to water, and hydrophilicity (Table 2). Newer
synthetic filters differ dramatically from conven-
tional filters used prior to the 1990s in their clear-
ance capacity and biocompatibility (49).
The KoA estimates the maximum clearance of
urea by the filter when QB and QD are infinite
(1,2,6). High-efficiency membranes are defined as
having a KOA >600 ml/minute (50) and much of the
gain in KoA relates to an increase in surface area.
The clearance of middle molecules such as B12 (40),
teicoplanin (47), and b2-microglobulin (1) can also
slightly increase with the use of a large surface area
filter. Clearance of protein-bound solutes can also
increase (18–20), although not consistently (51).
With high-flux membranes, there is improved
clearance of larger MW solutes relative to small
MW solutes (41,49). This concept reflects the
greater solute permeability of high-flux membranes.
Fig. 1. Influence of QD and molecular weight on mean solute
clearance at QB 150 ml/minute. Color indicates the type of filter,
where black-colored has a surface area of 0.6 m2 and gray-col-
ored has a surface area of 0.9 m2 (graphs redrawn from data in
Brunet et al (13)., with permission from Elsevier)
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The simultaneous use of more than one filter, or
even two distinct circuits, can increase clearance.
Using two filters in parallel circuits has the effect of
increasing the surface area for filtration and
improves clearance of small molecules; it may be of
particular benefit in larger sized patients (52). This
set-up can also increase the clearance of other small
and middle MW compounds (40), like iohexol (52).
In contrast, adding a second filter in series may
improve the overall clearance of small (19,53), mid-
dle molecules (40), and also protein-bound solutes
(19). This has also been applied to poisoning cases,
when two circuits were used to facilitate elimination
enhancement of metformin (54,55).
Limitations. Clearance of middle MW solutes
varies among types/brands of high-flux filters, which
limits generalizability. For example, the clearance of
b2-microglobulin clearance differed almost two-fold
between filters with similar surface area (56), which
may be due to other processes such as molecule
trapping and adsorption.
There are limited data about the cost–benefit
ratio of simultaneously using two filters/machines in
poisoned patients. Although either is anticipated to
increase clearance, more research is required to con-
firm its effect and role in clinical management. Cur-
rent evidence suggests that the benefit of either
configuration (series or parallel) provides an incre-
mental clearance gain of approximately 5–7%
(52,53); however, a potential downside in the use of
two filters is cost and that it may delay the start of
the procedure.
High-flux filters are capable of removing mole-
cules as large as myoglobin (MW 17,200 Da) by dif-
fusion, although significantly less than by
convection for this range of MW (57).
Addition of Albumin to Dialysate
The underlying principle of albumin dialysis is
that addition of albumin to the dialysate may facili-
tate clearance of highly protein-bound toxins
because the unbound fraction diffuses into the dial-
ysate side where it binds to albumin and is trapped.
This creates a protein-binding disequilibrium on the
blood side and more drug would become unbound
and cross the membrane to be cleared. These tech-
niques have been used in the treatment of intoxica-
tions with varying degrees of success and
supporting clinical data are scarce (58,59).
QB and QD influence solute clearance in albumin
dialysis (60). For example, in an in vitro model of
CVVHD with albumin-supplemented dialysate
(2.5% g/l), an increase in QD will greatly influence
the clearance of bound solutes, while increments in
QB had an almost null effect (15). A favorable
impact of larger albumin concentration on clearance
of protein-bound toxins has been reported for diaz-
epam (61), as well as for valproic acid and carba-
mazepine (15), but not for phenytoin (15). Also,
higher surface area filters increase clearance by
albumin dialysis compared with lower ones (15).
Other factors impacting clearance of extracorporeal
liver assist devices (ELADs) are pore size, place-
ment of filters, membrane material, amount and
active surface of adsorbers, as well as free fraction
of albumin-bound substances and time on therapy
(62).
Convection
During convection, the patient’s blood passes
through a circuit and makes contact with a semiper-
meable filter. A positive transmembrane pressure
forces water to cross the filter and solutes follow
the bulk movement of the solvent (water; known as
solvent drag). Convection allows middle molecules
to be cleared much more efficiently than with
diffusion. The only ECTR that utilizes convection
exclusively for clearance of uremic toxins is hemofil-
tration (HF). Large volumes of replacement fluid
are required and can be infused before (predilution),
after (postdilution), or before and after (mixed dilu-
tion) the hemofilter in continuous and intermittent
HF/HDF. The replacement fluid can also be infused
with a special filter design called mid-dilution in
intermittent hemofiltration. Operational characteris-
tics influencing solute clearance during convection
include QB, ultrafiltration rate (QUF), the site of
fluid replacement, and the type of hemofilter
(Tables 1 and 3).
Although convection is often used in intermit-
tent dialysis to remove excess fluid in ESRD, its
impact on solute clearance is likely negligible
because ultrafiltration during IHD rarely surpasses
25 ml/minute.
Maximization of the Blood and Ultrafiltration
Rates
Principles. Clearance increases when either QB
and/or QUF are increased, analogous to the princi-
ples previously discussed for diffusion. In continu-
ous venovenous HF (CVVH) and postdilution
intermittent HF, QB exceeds QUF, so QUF is the
rate-limiting step; QB may be the rate-limiting step
TABLE 2. Dialyzer classification
Surface area (m2) KUF (ml/h/mmHg) ß2-microglobulin clearance (ml/minute) Albumin loss Application
Conventional <1.5 m2 0–10 <20 0 HD
High-flux Variable 20–40 >40 + HD, HF, HDF
High-efficiency >1.5 m2 0–10 <20 + HD
Protein leaking >40 >80 +++ HD
HD, hemodialysis; HF, hemofiltration; HDF, hemodiafiltration.
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in intermittent HF with the predilution mode, as
QUF can be similar or exceed QB.
Clearance by postdilution HF is superior to pred-
ilution HF when all other factors are equal. How-
ever, the maximum possible QUF with postdilution
is less than that which can be achieved with predilu-
tion. To maximize clearance by convection, admin-
istration of the highest tolerable postdilution HF
should be combined with some predilution.
Supporting Data. The effect of convection on the
clearance of middle molecules is exemplified for b2-
microglobulin; its clearance by IHD when using a
high-flux membrane is 20–40 ml/minute under usual
IHD operational conditions, but when the same
membrane is used with HF, clearance is 100–
150 ml/minute (45,63). This is further supported by
studies with ß2-microglobulin and complement fac-
tor D (24,000 Da), although the achieved clearance
is highly dependent on QUF(45,64–71). The differ-
ence in clearances between convection and diffusion
increases as the solute’s MW increases. For exam-
ple, vancomycin removal (MW 1448 Da) is about
20% greater during convection compared with
diffusion. Daptomycin (MW 1620 Da) clearance is
>25% higher by HF than HD at standard CRRT
effluent rates (72).
The clearance of small and middle molecules
proportionately increases with higher QUF (13,14,
65,66,71) whether using intermittent HF, CVVH
(Fig. 2), or continuous venovenous hemodiafiltra-
tion (CVVHDF)(73). In postdilution HF, the clear-
ance of small molecules is approximately equal to
QUF. Increasing QUF to exceed 4–6 l/hour is associ-
ated with a smaller proportional increase in overall
clearance. Increasing QB allows a higher postdilu-
tion QUF without compromising the filtration frac-
tion (74). Once QUF exceeds 4–6 l/hour, QB should
be maximized to 350 or even 450 ml/minute if toler-
ated (75).
Although postdilution HF provides higher con-
vective clearances than predilution at the same QUF,
greater replacement volumes can be administered in
predilution HF so the maximum possible clearance
could exceed that achieved by postdilution HF. With
predilution HF alone, there is a decrease in the con-
centration of the solute, so each incremental increase
in QUF has a more modest impact on small nonpro-
tein-bound molecule removal (45,75), although the
effect remains significant, even for ß2-microglobulin
(45,75). In predilution HF, the QUF can be theoreti-
cally as high as 400 ml/minute during intermittent
HF (76,77). With CRRT, the total effluent can reach
8–10 l/hour with current machines.
Clearance is also proportional to QB (75), as
higher QB reduces the extent to which the predilu-
tion replacement fluid dilutes the solute concentra-
tion. For example, at a QUF of 2 l/hour, tripling QB
from 150 ml/minute to 450 ml/minute increases
urea clearances by approximately 15%; at a QUF of
6 l/hour, tripling QB rates from 150 to 450 ml/min-
ute increases urea clearances by approximately 35%
(45,75). Increases in QB have a more limited effect
on the removal of larger molecules such as ß2-mi-
croglobulin compared with smaller molecules (45).
The usual QB in intermittent HF is 300 ml/min-
ute, compared with 150–250 ml/minute in CRRT,
although higher flows are possible depending on the
vascular access.
Limitations. Although postdilution hemofiltra-
tion can be associated with enhanced clearance
compared with a similar QUF administered predilu-
tion, it has been argued that for small, middle, and
protein-bound molecules this advantage is of minor
clinical significance (13,65). However, in other stud-
ies, a 40% increase in clearance occurred as QUF
increased (45,66).
In postdilution HF, the maximum QUF depends,
in part, on QB and the relationship can be described
by the filtration fraction, which is calculated as QUF
divided by QB. The filtration fraction should be less
than 30% to avoid hemoconcentration and high fil-
ter transmembrane pressures (TMP), which impair
filter performance (74,77,78).
Postdilution HF is associated with an increased
risk of clotting of the filter and requires anticoagu-
lation, which is not essential in predilution (77).
Use of a Large High-Flux Filter, Particularly for
Middle-Sized Solutes
Principles. The clearance of middle MW solutes
depends, in part, on solvent drag due to ultrafiltration.
TABLE 3. Relative comparison of the influence of the different
parameters on the clearance of small and middle molecules in inter-
mittent hemodiafiltration
Increasing
surface
area from
1.4 to 2.2 m2
Increasing QB
from 300 to
500 ml/minute
Addition
of convection
Urea 6% 40% 18%
b2-
microglobulin
22% 16% 75%
Data adapted from Wizemann, 2001 (45).
Fig. 2. Influence of QUF and molecular weight on mean solute
clearance at a blood flow of 150 ml/minute. Color indicates the
type of filter, where black-colored has a surface area of 0.6 m2
and gray-colored has a surface area of 0.9 m2 (graphs redrawn
from data in Brunet et al (13)., with permission from Elsevier).
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Therefore, the preferred ECTR for middle molecules
is hemofiltration using large high-flux membranes.
Supporting Data. Most existing high-flux mem-
branes have a ß2-microglobulin clearance of at least
20 ml/minute and a KUF >20 ml/hour/mmHg (79);
this KUF value represents the current recommenda-
tion for filters used in intermittent haemodiafiltra-
tion (78).
When convection is performed in isolation, high-
efficiency and conventional dialysis filters have a
minor effect compared with lower efficiency filters
on the clearance of small (<500–1000 Da) (45,66,80)
and larger molecules (1,13,40,41,45,56,81). However,
clearances of middle-sized solutes up to 10,000 Da
are clearly higher with a high-flux membrane and
become negligible with a MW >20,000 Da (63,82).
Another advantage of a larger filter surface area
(for example, 2.2 m2 compared to 1.4 m2) is that it
can withstand greater transmembrane pressures for
a longer period of time (13), allowing higher QB
and convective fluxes across the membrane (45,74).
Newer dialyzer membranes have been developed
for certain clinical scenarios. Protein-leaking mem-
branes, also named high cut-off (HCO) or “super-
flux” membranes, are highly permeable membranes
with improved removal of protein-bound solutes
and larger sized unbound solutes (63). For example,
compared with high-flux filters, protein-leaking
membranes increase ß2-microglobulin removal,
although this is at the expense of a heavier albumin
loss (83). These filters have a more complex effect
than the simple leakage of albumin and its bound
constituents across their membrane (63). Current
applications include the removal of light chains in
multiple myeloma (84). Very high capacity filters
are also used during therapeutic plasma exchange
using a filtration technique. Protein-leaking mem-
branes have potential applications in toxicology for
poisons that are highly protein-bound, especially
considering that albumin loss likely has negligible
clinical significance when these filters are used for a
limited number of sessions (63).
Limitations. The material used for the filter
membrane can influence clearance. For example,
solute clearances with AN69 seem lower than with
other membranes (72,85–88). In convection, solutes
may be adsorbed to the filter. The effect is more
pronounced for middle and large MW molecules
and is maximal within the first hours after a filter
change (89–93). However, the impact of adsorption
cannot be easily predicted by analyzing the filter
and the MW of the poison (68). Therefore, it should
not be assumed that all high-flux hemofilters pro-
vide comparable clearance simply based on their
characteristics (66,69,74). Filter efficacy also
decreases with time, especially after 48 hours
(94,95). Recommendations from the manufacturers
include filter change every 48–72 hours to preserve
the filter clearance capacity, regardless of the
adsorptive process (91).
It is unclear whether protein-leaking membranes
offer benefits beyond those obtained with conven-
tional high-flux membranes, because data are lim-
ited (63).
Use of Convection and Diffusion
Diffusion and convection have a comparable
effect on the clearance of smaller MW molecules
(<500–1000 Da), while convection provides much
higher clearances for middle MW molecules (1000–
10,000 Da) compared with diffusion. Therefore,
clearance of small MW molecules can be enhanced
by adding convection to diffusion, thereby increas-
ing total effluent rate (96), although the opposite is
not true for middle MW molecules. As previously
mentioned, for each modality, the actual clearance
achieved will depend on the QB, QUF, or QD used.
Examples from the poisoning literature are limited,
but lithium clearance in one report was similar with
CVVH and CVVHD at similar effluent rates (96).
Although the two clearances are not additive,
there seems to be only a minimal interaction
between them in CVVHDF (13). However, in HDF,
ultrafiltration and predilution may have a negative
impact on transmembrane concentration gradients
(77,78). Nevertheless, the addition of convection
may improve clearance of some solutes, like phos-
phorus (97). With newer machines, the maximal
effluent flow in CRRT is 8–10 l/hour, while QUF
can reach 24 l/hour in predilution HDF, assuming a
QB of 350–400 ml/minute.
Adsorption
Adsorption is a process by which particles located
in the blood compartment bind reversibly or irre-
versibly to the surface of a column (or sorbent).
This process is central to hemoperfusion and is cov-
ered in detail in the dedicated article on hemoperfu-
sion presented in this issue.
Although adsorption may occur during diffusive
and especially convective techniques, its contribu-
tion to total clearance is variable, and cannot be
easily predicted by considering the type of filter
and/or the MW of the poison (68). Adsorption is
usually considered to have a minor effect on clear-
ance compared with convection and diffusion, is
more pronounced for middle and large MW mole-
cules, and largely occurs within the first hour after
a filter change (89–93).
Centrifugation
Centrifugation and convection are the major pro-
cesses implicated in plasmapheresis techniques. Cen-
trifugation separates the whole blood into various
components according to their specific gravity, and
is usually used to remove pathogenic proteins such
as antibodies. Centrifugation may also be useful to
remove large or protein-bound solutes located in
the plasma.
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Centrifugation can be performed intermittently or
continuously (98). With intermittent centrifugation,
blood is drawn in successive batches through flow
separators to remove a target volume of plasma.
With continuous-flow equipment, blood flows con-
tinuously into a rotating device in which red cells,
leukocytes, platelets, and plasma separate into
layers according to their respective specific gravity.
Any of these layer(s) can be removed, and the
remainder is returned to the patient along with a
replacement fluid. Continuous-flow centrifugation is
fully automated and is faster than intermittent cen-
trifugation (98).
Maximization of the Volume of Plasma
Exchanged
The major factor influencing clearance with cen-
trifugation is the total volume of plasma exchanged
per session (99). In therapeutic plasma exchange
(TPE), a single exchange of one plasma volume
(defined as a patient’s entire plasma volume and
corresponds to 3 l for a 70 kg patient) removes
63% of all solutes in plasma. An exchange of 2
plasma volumes removes 86% of solutes, while a
third would decrease initial solute concentration by
95% (100,101).
In the treatment of a poisoned patient, the Amer-
ican Society for Apheresis (ASFA) guidelines rec-
ommend an exchange volume of one to two total
plasma volumes per day until clinical symptoms
have decreased and the release of toxin from tissues
is no longer significant (102). However, as acknowl-
edged, this recommendation was based on limited
data.
Choice of Replacement Fluid
The choice of the replacement volume may be
guided by the affinity of the poison to its main
binding protein. For example, the ASFA guidelines
suggest that fresh frozen plasma may be the most
appropriate choice in poisoning from drugs like
quinidine, imipramine, and propranolol, as these
drugs have a great affinity for alpha-1-acid glyco-
protein (102). However, this is debatable because of
their large VD, which limits total body removal, and
the relatively small concentration of alpha-1-acid
glycoprotein in plasma (21). Finally, in TPE with
filtration, the surface area of the filter does not seem
to significantly influence clearances, which is differ-
ent than for dialysis or convection (99).
Clearance Parameters Applicable to All
Processes
Treatment Time
Assuming that a poison is removable by ECTR
and there is no filter saturation, the concentration
of poison in the blood would decrease steadily and
progressively, usually according to first-order kinet-
ics. For some molecules, the treatment time is the
most important factor determining poison removal
(81), so the “routine” 4-hour treatment reserved for
patients with end-stage renal disease (ESRD) should
be challenged in the treatment of a poisoned
patient. Classical examples include prolonged IHD
for poisoning from lithium or aspirin (103).
Location, Length, and Size of the
Intravascular Catheter
The maximum achievable QB depends on the
location of the intravascular catheter, its lumen size,
and length. A recent large randomized trial from
the Cathedia study group showed that catheters
placed in the right jugular or the femoral vein are
associated with less dysfunction than those placed
in the left jugular vein (104); the subclavian site is
not favored in patients at risk for ESRD (105),
although its recirculation rate is similar to that in
the jugular vein (106). If a femoral catheter is used,
its length should be longer than 20 cm, ideally
25 cm, to minimize recirculation (104,106–108).
These considerations should be weighed against
the experience of the operator, complication rate,
and the time required to install the catheter, as well
as the delay to perform a X-ray confirming the posi-
tion of the subclavian or jugular catheter. While
these data are derived from diffusion-based tech-
niques, they are likely valid for convection as well.
For TPE by centrifugation and filtration, a central
catheter also allows optimizing blood flow rate and
clearance (109,110). However, as the QB is much
lower in TPE than with other techniques, the cathe-
ter location, size, and length are not as important
as with other techniques. As an example, the QB is
usually 100 ml/minute for TPE with centrifugation
(104,105) and 100–200 ml/minute for TPE with
filtration (99).
Administration of Anticoagulation According
to Usual Procedure
Anticoagulation is usually required for ECTR to
ensure continuing efficacy of the procedure. Clotting
reduces filter/column performance and may reduce
the overall effect of ECTR if the circuit needs to
be changed. During diffusion-based procedures,
heparin-free chronic IHD does not appear to signifi-
cantly reduce solute clearance if there is no clotting
of the circuit (111). Studies in acute settings are
required to validate this observation.
Clinical experience suggests that predilution inter-
mittent HDF can be performed without anticoagu-
lation, while postdilution intermittent HDF usually
requires anticoagulation because of increased viscos-
ity of blood in the hemofilter. In CRRT, filter life is
independent of heparin dose (including 700 U/hour)
(112). However, filter life is significantly shorter
when postdilution is used instead of predilution
(113,114). Anticoagulation is required for TPE,
whereby citrate is most frequently used during cen-
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trifugation, while heparin is used for filtration (98).
The influence of anticoagulation on the elimination
of poison needs to be further studied in TPE.
Conclusion
The use of an ECTR for enhanced elimination in
poisoned patients can be effective for a limited
number of poisons. Optimizing extracorporeal clear-
ance can benefit patients by reducing toxicity, but it
may also reduce the utilization of health resources
by shortening the duration of treatment and overall
hospital length of stay.
In this manuscript, we aimed to review the vari-
ous components of ECTR and highlight the modali-
ties and parameters that are most likely to enhance
clearance. However, data supporting some of these
recommendations are limited, particularly in the
context of poisoning. Therefore, clinical decisions
should be made on a case-by-case basis by specifi-
cally considering the actual poison, clinical circum-
stances, patient characteristics, and available
techniques.
References
1. Mandolfo S, Malberti F, Imbasciati E, Cogliati P, Gauly A: Impact
of blood and dialysate flow and surface on performance of new
polysulfone hemodialysis dialyzers. Int J Artif Organs 26:113–120,
2003
2. Allen R, Frost TH, Hoenich NA: The influence of the dialysate flow
rate on hollow fiber hemodialyzer performance. Artif Organs
19:1176–1180, 1995
3. Leypoldt JK, Cheung AK, Agodoa LY, Daugirdas JT, Greene T,
Keshaviah PR: Hemodialyzer mass transfer-area coefficients for
urea increase at high dialysate flow rates. The Hemodialysis
(HEMO) Study. Kidney Int 51:2013–2017, 1997
4. Ouseph R, Ward RA: Increasing dialysate flow rate increases dia-
lyzer urea mass transfer-area coefficients during clinical use. Am J
Kidney Dis 37:316–320, 2001
5. Borzou SR, Gholyaf M, Zandiha M, Amini R, Goodarzi MT,
Torkaman B: The effect of increasing blood flow rate on dialysis
adequacy in hemodialysis patients. Saudi J Kidney Dis Transpl
20:639–642, 2009
6. Munshi R, Ahmad S: Comparison of urea clearance in low-effi-
ciency low-flux vs. high-efficiency high-flux dialyzer membrane with
reduced blood dialysate flow An in vitro analysis. Hemodial Int
18:172–174, 2014
7. Gutzwiller JP, Schneditz D, Huber AR, Schindler C, Garbani E,
Zehnder CE: Increasing blood flow increases kt/V(urea) and potas-
sium removal but fails to improve phosphate removal. Clin Nephrol
59:130–136, 2003
8. Ward RA: Blood flow rate: an important determinant of urea clear-
ance and delivered Kt/V. Adv Ren Replace Ther 6:75–79, 1999
9. Hauk M, Kuhlmann MK, Riegel W, Kohler H: In vivo effects of
dialysate flow rate on Kt/V in maintenance hemodialysis patients.
Am J Kidney Dis 35:105–111, 2000
10. Bhimani JP, Ouseph R, Ward RA: Effect of increasing dialysate
flow rate on diffusive mass transfer of urea, phosphate and beta2-
microglobulin during clinical haemodialysis. Nephrol Dial Trans-
plant 25: 3990–3995, 2010
11. Davenport A, Will EJ, Davison AM: Effect of the direction of dial-
ysate flow on the efficiency of continuous arteriovenous haemodialy-
sis. Blood Purif 8:329–336, 1990
12. Relton S, Greenberg A, Palevsky PM: Dialysate and blood flow
dependence of diffusive solute clearance during CVVHD. ASAIO J
38:M691–M696, 1992
13. Brunet S, Leblanc M, Geadah D, Parent D, Courteau S, Cardinal
J: Diffusive and convective solute clearances during continuous
renal replacement therapy at various dialysate and ultrafiltration
flow rates. Am J Kidney Dis 34:486–492, 1999
14. Gong D, Ji D, Xie H, Xu B, Liu Y, Li L: The effects of dialysate
and ultrafiltration flow rate on solute clearance during continuous
renal replacement therapy. Zhonghua Nei Ke Za Zhi 40:183–186,
2001
15. Churchwell MD, Pasko DA, Smoyer WE, Mueller BA: Enhanced
clearance of highly protein-bound drugs by albumin-supplemented
dialysate during modeled continuous hemodialysis. Nephrol Dial
Transplant 24:231–238, 2009
16. Bonnardeaux A, Pichette V, Ouimet D, Geadah D, Habel F, Cardi-
nal J: Solute clearances with high dialysate flow rates and glucose
absorption from the dialysate in continuous arteriovenous hemodi-
alysis. Am J Kidney Dis 19:31–38, 1992
17. Wilson FP, Bachhuber MA, Caroff D, Adler R, Fish D, Berns J:
Low cefepime concentrations during high blood and dialysate flow
continuous venovenous hemodialysis. Antimicrob Agents Chemother
56:2178–2180, 2012
18. Meyer TW, Leeper EC, Bartlett DW, Depner TA, Lit YZ, Robert-
son CR, Hostetter TH: Increasing dialysate flow and dialyzer mass
transfer area coefficient to increase the clearance of protein-bound
solutes. J Am Soc Nephrol 15:1927–1935, 2004
19. Luo FJ, Patel KP, Marquez IO, Plummer NS, Hostetter TH, Meyer
TW: Effect of increasing dialyzer mass transfer area coefficient and
dialysate flow on clearance of protein-bound solutes: a pilot cross-
over trial. Am J Kidney Dis 53:1042–1049, 2009
20. Sirich TL, Luo FJ, Plummer NS, Hostetter TH, Meyer TW: Selec-
tively increasing the clearance of protein-bound uremic solutes.
Nephrol Dial Transplant 27:1574–1579, 2012
21. Roberts DM, Buckley NA: Pharmacokinetic considerations in clini-
cal toxicology: clinical applications. Clin Pharmacokinet 46:897–939,
2007
22. Franssen EJ, van Essen GG, Portman AT, de Jong J, Go G, Steg-
eman CA, Uges DR: Valproic acid toxicokinetics: serial hemodialy-
sis and hemoperfusion. Ther Drug Monit 21:289–292, 1999
23. Lanese DM, Alfrey PS, Molitoris BA: Markedly increased clearance
of vancomycin during hemodialysis using polysulfone dialyzers. Kid-
ney Int 35:1409–1412, 1989
24. Bosl R, Shideman JR, Meyer RM, Buselmeier TJ, von Hartitzsch
B, Kjellstrand CM: Effects and complications of high efficiency dial-
ysis. Nephron 15:151–160, 1975
25. Voiculescu A, Hefter H, Falck M, Kutkuhn B, Grabensee B:
Hemodialysis in severe lithium intoxication [German]. Intensivmed
Notfallmed 32:433–437, 1995
26. Lee CS, Peterson JC, Marbury TC: Comparative pharmacokinetics
of theophylline in peritoneal dialysis and hemodialysis. J Clin Phar-
macol 23:274–280, 1983
27. Pond SM: Extracorporeal techniques in the treatment of poisoned
patients. Med J Aust 154:617–622, 1991
28. Holubek WJ, Hoffman RS, Goldfarb DS, Nelson LS: Use of
hemodialysis and hemoperfusion in poisoned patients. Kidney Int
74:1327–1334, 2008
29. Fertel BS, Nelson LS, Goldfarb DS: Extracorporeal removal tech-
niques for the poisoned patient: a review for the intensivist. J Inten-
sive Care Med 25:139–148, 2010
30. Manley HJ, Bridwell DL, Elwell RJ, Bailie GR: Influence of perito-
neal dialysate flow rate on the pharmacokinetics of cefazolin. Perit
Dial Int 23:469–474, 2003
31. Ullian ME, Parker H, Sibbald LD, Peabody AM, Schattner P, Jen-
sen JF: Effect of increasing dialysate flow rates on adequacy of peri-
toneal dialysis. Perit Dial Int 20:571–574, 2000
32. Rubin J, Adair C, Barnes T, Bower J: Dialysate flow rate and peri-
toneal clearance. Am J Kidney Dis 4:260–267, 1984
33. Robson M, Oreopoulos DG, Izatt S, Ogilvie R, Rapoport A,
deVeber GA: Influence of exchange volume and dialysate flow rate
on solute clearance in peritoneal dialysis. Kidney Int 14:486–490,
1978
34. Freida P, Issad B: Continuous flow peritoneal dialysis: assessment
of fluid and solute removal in a high-flow model of “fresh dialysate
single pass”. Perit Dial Int 23:348–355, 2003
35. Ronco C, Dell’Aquila R, Bonello M, Gloukhoff A, Amerling R,
Cruz C, Levin N: Continuous flow peritoneal dialysis: a new double
lumen catheter. Int J Artif Organs 26:984–990, 2003
36. Szepietowski T, Weyde W, Stefanska-Bac E: Methanol elimination
in peritoneal dialysis [Polish]. Pol Tyg Lek 30 (22):933–935, 1975
37. Kan G, Jenkins I, Rangan G, Woodroffe A, Rhodes H, Joyce D:
Continuous haemodiafiltration compared with intermittent haemod-
ialysis in the treatment of methanol poisoning. Nephrol Dial Trans-
plant 18:2665–2667, 2003
38. Brandes JC, Packard WJ, Watters SK, Fritsche C: Optimization of
dialysate flow and mass transfer during automated peritoneal dialy-
sis. Am J Kidney Dis 25:603–610, 1995
39. Aasarod K, Wideroe TE, Flakne SC: A comparison of solute clear-
ance and ultrafiltration volume in peritoneal dialysis with total or
fractional (50%) intraperitoneal volume exchange with the same
dialysate flow rate. Nephrol Dial Transplant 12:2128–2132, 1997
378 Bouchard et al.
40. Eloot S, de Vos JY, de Vos F, Hombrouckx R, Verdonck P: Middle
molecule removal in low-flux polysulfone dialyzers: impact of flows
and surface area on whole-body and dialyzer clearances. Hemodial
Int 9:399–408, 2005
41. Leypoldt JK, Cheung AK: Removal of high-molecular-weight sol-
utes during high-efficiency and high-flux haemodialysis. Nephrol
Dial Transplant 11:329–335, 1996
42. Trerotola SO, Shah H, Johnson M, Namyslowski J, Moresco K,
Patel N, Kraus M, Gassensmith C, Ambrosius WT: Randomized
comparison of high-flow versus conventional hemodialysis catheters.
J Vasc Interv Radiol 10:1032–1038, 1999
43. Szabo J, Locking-Cusolito H: The impact of increased blood flow
rates on recirculation in central venous hemodialysis catheters.
Nephrol Nurs J 28:639–641, 2001
44. Pannu N, Jhangri GS, Tonelli M: Optimizing dialysis delivery in
tunneled dialysis catheters. ASAIO J 52:157–162, 2006
45. Wizemann V, Kulz M, Techert F, Nederlof B: Efficacy of
haemodiafiltration. Nephrol Dial Transplant 16(Suppl 4):27–30,
2001
46. Azar AT: Increasing dialysate flow rate increases dialyzer urea clear-
ance and dialysis efficiency: an in vivo study. Saudi J Kidney Dis
Transpl 20:1023–1029, 2009
47. Wolter K, Claus M, Wagner K, Fritschka E: Teicoplanin pharma-
cokinetics and dosage recommendations in chronic hemodialysis
patients and in patients undergoing continuous veno-venous hemod-
ialysis. Clin Nephrol 42:389–397, 1994
48. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek
JW, Allon M, Bailey J, Delmez JA, Depner TA, Dwyer JT, Levey
AS, Levin NW, Milford E, Ornt DB, Rocco MV, Schulman G,
Schwab SJ, Teehan BP, Toto R; Hemodialysis Study G: Effect of
dialysis dose and membrane flux in maintenance hemodialysis. N
Engl J Med 347: 2010–2019, 2002
49. Matzke GR: Status of hemodialysis of drugs in 2002. J Pharm Pract
15:405–418, 2002
50. Schuerer DJ, Brophy PD, Maxvold NJ, Kudelka T, Bunchman TE:
High-efficiency dialysis for carbamazepine overdose. J Toxicol Clin
Toxicol 38:321–323, 2000
51. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder
R: Intradialytic removal of protein-bound uraemic toxins: role of
solute characteristics and of dialyser membrane. Nephrol Dial Trans-
plant 15:50–57, 2000
52. Powers KM, Wilkowski MJ, Helmandollar AW, Koenig KG, Bol-
ton WK: Improved urea reduction ratio and Kt/V in large hemodi-
alysis patients using two dialyzers in parallel. Am J Kidney Dis
35:266–274, 2000
53. Fritz BA, Doss S, McCann LM, Wrone EM: A comparison of dual
dialyzers in parallel and series to improve urea clearance in large he-
modialysis patients. Am J Kidney Dis 41:1008–1015, 2003
54. Panzer U, Kluge S, Kreymann G, Wolf G: Combination of inter-
mittent haemodialysis and high-volume continuous haemofiltration
for the treatment of severe metformin-induced lactic acidosis. Neph-
rol Dial Transplant 19:2157–2158, 2004
55. Friesecke S, Abel P, Kraft M, Gerner A, Runge S: Combined renal
replacement therapy for severe metformin-induced lactic acidosis.
Nephrol Dial Transplant 21:2038–2039, 2006
56. Ouseph R, Hutchison CA, Ward RA: Differences in solute removal
by two high-flux membranes of nominally similar synthetic poly-
mers. Nephrol Dial Transplant 23:1704–1712, 2008
57. Maduell F, Navarro V, Cruz MC, Torregrosa E, Garcia D, Simon
V, Ferrero JA: Osteocalcin and myoglobin removal in on-line hemo-
diafiltration versus low- and high-flux hemodialysis. Am J Kidney
Dis 40:582–589, 2002
58. Sen S, Ratnaraj N, Davies NA, Mookerjee RP, Cooper CE, Patsa-
los PN, Williams R, Jalan R: Treatment of phenytoin toxicity by
the molecular adsorbents recirculating system (MARS). Epilepsia
44:265–267, 2003
59. Askenazi DJ, Goldstein SL, Chang IF, Elenberg E, Feig DI: Man-
agement of a severe carbamazepine overdose using albumin-
enhanced continuous venovenous hemodialysis. Pediatrics 113:406–
409, 2004
60. Peszynski P, Klammt S, Peters E, Mitzner S, Stange J, Schmidt R:
Albumin dialysis: single pass vs. recirculation (MARS). Liver 22
(Suppl 2):40–42, 2002
61. Drexler K, Baustian C, Richter G, Ludwig J, Ramlow W, Mitzner
S: Albumin dialysis molecular adsorbents recirculating system:
impact of dialysate albumin concentration on detoxification efficacy.
Ther Apher Dial 13:393–398, 2009
62. Krisper P, Stadlbauer V, Stauber RE: Clearing of toxic substances:
are there differences between the available liver support devices?
Liver Int 31(Suppl 3):5–8, 2011
63. Ward RA: Protein-leaking membranes for hemodialysis: a new class
of membranes in search of an application? J Am Soc Nephrol
16:2421–2430, 2005
64. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W: A
comparison of on-line hemodiafiltration and high-flux hemodialy-
sis: a prospective clinical study. J Am Soc Nephrol 11:2344–2350,
2000
65. Bammens B, Evenepoel P, Verbeke K, Vanrenterghem Y: Removal
of the protein-bound solute p-cresol by convective transport: a ran-
domized crossover study. Am J Kidney Dis 44:278–285, 2004
66. Troyanov S, Cardinal J, Geadah D, Parent D, Courteau S, Caron
S, Leblanc M: Solute clearances during continuous venovenous hae-
mofiltration at various ultrafiltration flow rates using Multiflow-100
and HF1000 filters. Nephrol Dial Transplant 18:961–966, 2003
67. Gong X: Evaluation of Hemperfusion in early treatment of acute
organophosphoris pesticide poisoning. Acta Acad Med Nantong 24
(2):201–202, 2004
68. Yamashita AC: Mechanisms of solute and fluid removal in hemo-
diafiltration. Contrib Nephrol 158:50–56, 2007
69. Ahrenholz PG, Winkler RE, Michelsen A, Lang DA, Bowry SK:
Dialysis membrane-dependent removal of middle molecules during
hemodiafiltration: the beta2-microglobulin/albumin relationship.
Clin Nephrol 62:21–28, 2004
70. Maduell F, del Pozo C, Garcia H, Sanchez L, Hdez-Jaras J, Albero
MD, Calvo C, Torregrosa I, Navarro V: Change from conventional
haemodiafiltration to on-line haemodiafiltration. Nephrol Dial
Transplant 14:1202–1207, 1999
71. Panich A, Tiranathanagul K, Praditpornsilpa K, Eiam-Ong S: The
effectiveness of on-line hemodiafiltration on beta-2 microglobulin
clearance in end stage renal disease. J Med Assoc Thai 89(Suppl 2):
S1–S8, 2006
72. Churchwell MD, Pasko DA, Mueller BA: Daptomycin clearance
during modeled continuous renal replacement therapy. Blood Purif
24:548–554, 2006
73. Lau AH, Kronfol NO: Effect of continuous hemofiltration on phe-
nytoin elimination. Ther Drug Monit 16:53–57, 1994
74. Penne EL, van der Weerd NC, Bots ML, van den Dorpel MA,
Grooteman MP, Levesque R, Nube MJ, Ter Wee PM, Blankestijn
PJ; investigators C: Patient- and treatment-related determinants of
convective volume in post-dilution haemodiafiltration in clinical
practice. Nephrol Dial Transplant 24: 3493–3499, 2009
75. Gashti CN, Rodby RA, Huang Z, Gao D, Zhang W: Effects of
high blood flow and high pre-dilution replacement fluid rates on
small solute clearances in hemofiltration. Blood Purif 32:266–270,
2011
76. Altieri P, Sorba G, Bolasco P, Asproni E, Ledebo I, Cossu M, Ferr-
ara R, Ganadu M, Cadinu F, Serra G, Cabiddu G, Sau G, Casu D,
Passaghe M, Bolasco F, Pistis R, Ghisu T; Second Sardinian Multi-
centre S: Predilution haemofiltration–the Second Sardinian Multi-
centre Study: comparisons between haemofiltration and
haemodialysis during identical Kt/V and session times in a long-
term cross-over study. Nephrol Dial Transplant 16:1207–1213, 2001
77. Colussi G, Frattini G: Quantitative analysis of convective dose in
hemofiltration and hemodiafiltration: “predilution” vs. “postdilu-
tion” reinfusion. Hemodial Int 11:76–85, 2007
78. Tattersall JE, Ward RA; Group E: Online haemodiafiltration: defi-
nition, dose quantification and safety revisited. Nephrol Dial Trans-
plant 28:542–550, 2013
79. Clark WR, Ronco C: Determinants of haemodialyser performance
and the potential effect on clinical outcome. Nephrol Dial Trans-
plant 16(Suppl 5):56–60, 2001
80. Jeffrey RF, Khan AA, Prabhu P, Todd N, Goutcher E, Will EJ,
Davison AM: A comparison of molecular clearance rates during
continuous hemofiltration and hemodialysis with a novel volumetric
continuous renal replacement system. Artif Organs 18:425–428, 1994
81. Ratanarat R, Brendolan A, Volker G, Bonello M, Salvatori G, An-
drikos E, Yavuz A, Crepaldi C, Ronco C: Phosphate kinetics during
different dialysis modalities. Blood Purif 23:83–90, 2005
82. Cheung AK, Leypoldt JK: The hemodialysis membranes: a histori-
cal perspective, current state and future prospect. Semin Nephrol
17:196–213, 1997
83. Pellicano R, Polkinghorne KR, Kerr PG: Reduction in beta2-micro-
globulin with super-flux versus high-flux dialysis membranes: results
of a 6-week, randomized, double-blind, crossover trial. Am J Kidney
Dis 52:93–101, 2008
84. Martin-Reyes G, Toledo-Rojas R, Torres-de Rueda A, Sola-Moy-
ano E, Blanca-Martos L, Fuentes-Sanchez L, Martinez-Esteban
MD, Diez-de los Rios MJ, Bailen-Garcia A, Gonzalez-Molina M,
Garcia-Gonzalez I: Haemodialysis using high cut-off dialysers for
treating acute renal failure in multiple myeloma. Nefrologia 32:35–
43, 2012
85. Matzke GR, Frye RF, Joy MS, Palevsky PM: Determinants of cef-
triaxone clearance by continuous venovenous hemofiltration and he-
modialysis. Pharmacotherapy 20:635–643, 2000
86. Joy MS, Matzke GR, Frye RF, Palevsky PM: Determinants of
vancomycin clearance by continuous venovenous hemofiltration and
continuous venovenous hemodialysis. Am J Kidney Dis 31:1019–
1027, 1998
87. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, Depestel DD,
Sorgel F, Kinzig M, Jakob V, Mueller BA: Ertapenem clearance
PARAMETERS TO ENHANCE CLEARANCE 379
during modeled continuous renal replacement therapy. Int J Artif
Organs 31:1027–1034, 2008
88. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Muel-
ler B: Telavancin and hydroxy propyl-beta-cyclodextrin clearance
during continuous renal replacement therapy: an in vitro study. Int
J Artif Organs 32:745–751, 2009
89. Choi G, Gomersall CD, Lipman J, Wong A, Joynt GM, Leung P,
Ramsay SJ, Ho OM: The effect of adsorption, filter material and
point of dilution on antibiotic elimination by haemofiltration an in
vitro study of levofloxacin. Int J Antimicrob Agents 24:468–472, 2004
90. Davies JG, Kingswood JC, Sharpstone P, Street MK: Drug removal
in continuous haemofiltration and haemodialysis. Br J Hosp Med
54:524–528, 1995
91. De Vriese AS, Colardyn FA, Philippe JJ, Vanholder RC, De Sutter
JH, Lameire NH: Cytokine removal during continuous hemofiltra-
tion in septic patients. J Am Soc Nephrol 10:846–853, 1999
92. Kronfol NO, Lau AH, Colon-Rivera J, Libertin CL: Effect of
CAVH membrane types on drug-sieving coefficients and clearances.
ASAIO Trans 32:85–87, 1986
93. Birk HW, Kistner A, Wizemann V, Schutterle G: Protein adsorp-
tion by artificial membrane materials under filtration conditions. Ar-
tif Organs 19:411–415, 1995
94. Boyle M, Wyndham K, Jacobs S, Torda TA: Comparative clear-
ance performance of two dialyser units used in the CVVHD mode.
Aust Crit Care 8:20–25, 1995
95. Pasko DA, Churchwell MD, Salama NN, Mueller BA: Longitudinal
hemodiafilter performance in modeled continuous renal replacement
therapy. Blood Purif 32:82–88, 2011
96. Hazouard E, Ferrandiere M, Rateau H, Doucet O, Perrotin D, Leg-
ras A: Continuous veno-venous haemofiltration versus continuous
veno-venous haemodialysis in severe lithium self-poisoning: a toxic-
okinetics study in an intensive care unit. Nephrol Dial Transplant
14:1605–1606, 1999
97. Lornoy W, De Meester J, Becaus I, Billiouw JM, Van Malderen PA,
Van Pottelberge M: Impact of convective flow on phosphorus removal
in maintenance hemodialysis patients. J Ren Nutr 16:47–53, 2006
98. Madore F: Plasmapheresis technical aspects and indications. Crit
Care Clin 18(2):375–392, 2002
99. Tan HK, Hart G: Plasma filtration. Ann Acad Med Singapore
34:615–624, 2005
100. Jones JS, Dougherty J: Current status of plasmapheresis in toxicol-
ogy. Ann Emerg Med 15:474–482, 1986
101. Shelat SG: Practical considerations for planning a therapeutic
apheresis procedure. Am J Med 123:777–784, 2010
102. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linen-
berger ML, Marques MB, Sarode R, Schwartz J, Weinstein R, Shaz
BH; Apheresis Applications Committee of the American Society for
A: Guidelines on the use of therapeutic apheresis in clinical
practice–evidence-based approach from the Apheresis Applications
Committee of the American Society for Apheresis. J Clin Apher
25:83–177, 2010
103. Treysman L, Meehan TJ, Schlieben DJ, Ducre B, Erickson TB:
Pharmacokinetic Modeling of Lithium Elimination During 67 Con-
tinuous Hours of High Flux Hemodialysis (abstract). Clin Toxicol
48:647, 2010
104. Parienti JJ, Megarbane B, Fischer MO, Lautrette A, Gazui N,
Marin N, Hanouz JL, Ramakers M, Daubin C, Mira JP,
Charbonneau P, du Cheyron D; Cathedia Study G: Catheter dys-
function and dialysis performance according to vascular access
among 736 critically ill adults requiring renal replacement ther-
apy: a randomized controlled study. Crit Care Med 38:1118–1125,
2010
105. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kid-
ney Injury Work Group: KDIGO Clinical Practice Guideline for
Acute Kidney Injury. Kidney Int Suppl 2: 1–138, 2012
106. Kelber J, Delmez JA, Windus DW: Factors affecting delivery of
high-efficiency dialysis using temporary vascular access. Am J Kid-
ney Dis 22:24–29, 1993
107. Leblanc M, Fedak S, Mokris G, Paganini EP: Blood recirculation
in temporary central catheters for acute hemodialysis. Clin Nephrol
45:315–319, 1996
108. Little MA, Conlon PJ, Walshe JJ: Access recirculation in temporary
hemodialysis catheters as measured by the saline dilution technique.
Am J Kidney Dis 36:1135–1139, 2000
109. Okafor C, Kalantarinia K: Vascular access considerations for thera-
peutic apheresis procedures. Semin Dial 25:140–144, 2012
110. Schonermarck U, Bosch T: Vascular access for apheresis in inten-
sive care patients. Ther Apher Dial 7:215–220, 2003
111. McGill RL, Blas A, Bialkin S, Sandroni SE, Marcus RJ: Clinical
consequences of heparin-free hemodialysis. Hemodial Int 9:393–398,
2005
112. Martin PY, Chevrolet JC, Suter P, Favre H: Anticoagulation in
patients treated by continuous venovenous hemofiltration: a retro-
spective study. Am J Kidney Dis 24:806–812, 1994
113. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R: Pre-dilu-
tion vs. post-dilution during continuous veno-venous hemofiltration:
impact on filter life and azotemic control. Nephron Clin Pract 94:
c94–c98, 2003
114. van der Voort PH, Gerritsen RT, Kuiper MA, Egbers PH, Kingma
WP, Boerma EC: Filter run time in CVVH: pre- versus post-dilu-
tion and nadroparin versus regional heparin-protamine anticoagula-
tion. Blood Purif 23:175–180, 2005
380 Bouchard et al.
